Epalrestat is an aldose reductase inhibitor.Long-term treatment with epalrestat is well tolerated and can effectively delay the progression of diabetic neuropathy and ameliorate the associated symptoms of the disease particularly in subjects with good glycemic control and limited microangiopathy.
This page contains content from the copyrighted Wikipedia article "Epalrestat"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
